RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Brand Name :
abthrax
Synonyms :
Raxibacumab
Class :
Monoclonal antibody
Dosage Forms & Strengths
Intravenous solution
50mg/ml
40
mg/kg
single dose infusion
Intravenous (IV)
for over 2.25 hour
Diphenhydramine should be administered 1 hour before the infusion
Dosage Forms & Strengths
Intravenous solution
50mg/ml
15kgs:80mg/kg intravenously
≥15 to 50kg:60mg/kg intravenously
>50kg:40mg/kg intravenously, single dose infusion for 2.25 hour
Diphenhydramine should be administered 1 hour before the infusion
may decrease the therapeutic effects of Fc receptor binding agents
it may enhance the adverse effects when combined with aducanumab
Frequency defined:
1-10%
Pain in extremity
Somnolence
Rash pruritis
<1%
Vertigo
Fatigue
Anemia
Muscle spasm
Leukopenia
Syncope vasovagal
Palpitations
lymphadenopathy
Insomnia
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: raxibacumab
Pronounced: rax” ee bak’ ue mab
Why do we use raxibacumab?
It is used to treat inhalational anthrax in adults and pediatrics